|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Twin Cities Startup, Mardil Inc. Raises $6 Million From Malaysia
2/1/2013 8:36:42 AM
For many increasingly risk-averse med-tech venture capitalists, Mardil Medical probably isn't an ideal portfolio company. Before it can generate revenue, the Plymouth-based company must navigate the Food and Drug Administration's longest and most capital-intensive route to regulatory approval. Moreover, its technology incorporates assets acquired from a failed startup that spent more than $100 million in venture capital before shutting down after a protracted and high-profile battle with the FDA. Those challenges didn't stop Mardil CEO Jim Buck from seeking capital to fund his business, which is developing technology that treats a heart condition called functional mitral valve regurgitation. But it did help motivate him to think creatively. Since Mardil — like many med-tech companies — planned to conduct clinical trials overseas, he decided it would make sense to pursue capital there, too. Buck talked with Dale Wahlstrom, CEO of Life Sceince Alley, who pointed Buck to the trade group's innovation network and helped connect Mardil with Tractus Asia Ltd., a business consulting firm. Tractus introduced Buck to Malaysia's innovation agency, Agensi Inovasi Malaysia (AIM). The result: Mardil came home with $6.125 million in a round of funding led by AIM. And he expects to close an another $5 million later this year.
|
|
|
|
|
|
|
|
|
|
|